ETON Eton Pharmaceuticals

Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020

Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020

DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and operating results on Thursday, November 12, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT). 

The live webcast can be accessed on the investors section of Eton’s website at /. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5092872. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products in its late-stage pipeline, including five that have been submitted to the FDA.

Investor Contact:

David Krempa

 

612-387-3740

EN
04/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eton Pharmaceuticals

 PRESS RELEASE

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results o...

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In:        (800) 715-9871 or (646) 307-196...

 PRESS RELEASE

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application ...

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company’s New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, has been accepte...

 PRESS RELEASE

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3...

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution. “Eton’s addition to the Russell 2000 and Russell 3000 Indexes is a sign...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 14, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch